Gerber stage 3
Selected indexed studies
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. (N Engl J Med, 2025) [PMID:40305708]
- Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial. (N Engl J Med, 2025) [PMID:39665649]
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. (N Engl J Med, 2017) [PMID:29117498]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. (2025) pubmed
- Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial. (2025) pubmed
- First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. (2017) pubmed
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. (2015) pubmed
- A phase 3 trial of bevacizumab in ovarian cancer. (2011) pubmed
- Adjuvant trastuzumab in HER2-positive breast cancer. (2011) pubmed
- CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. (2022) pubmed
- Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial. (2021) pubmed
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. (2017) pubmed
- Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline. (2024) pubmed